Research programme: anti-cancer therapeutic - CJ Cheiljedang CorporationAlternative Names: CJ-12537
Latest Information Update: 16 Jul 2016
Price : $50
At a glance
- Originator CJ Cheiljedang Corp.
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in South Korea
- 31 Dec 2012 Preclinical trials in Cancer in South Korea (unspecified route)